Catch up with our weekly roundup
Selecta chooses Sanofi for $38m series E
Sanofi’s corporate venturing unit was among the new investors in a round that will support the advancement of Selecta’s gout treatment through Phase 1 trials.
Ramot sees Aerie collaboration
Tel Aviv’s tech transfer unit Ramot to partner Aerie Pharmaceuticals on glaucoma.
Celtic turns whisky into funding
Edinburgh Napier’s Celtic Renewables secures £11m ($16.92m) award to turn whisky dregs into biofuel.
Manchester and AstraZeneca to find the right treatment
Collaboration between Manchester and AstraZeneca worth £11.5m targets personalised oncology care.
No hands on the wheel for Toyota
Toyota unveils plans to invest $50m into AI research at MIT and Stanford for intelligent vehicles.
Yabao moves on cancer with South Australia
Yabao and South Australia University sign collaboration agreement to identify treatments for cancer.
Chip manufacturer Intel invest $50m into ten-year deal with Delft University of Technology on quantum computing.
Sanifit cleans up with $41m series C
Lundbeck, Baxter and La Caixa have contributed to a series C round that will support clinical trials for Sanifit’s treatments for dialysis patients.
Oxford lets Animal out the zoo
Oxford forms Animal Dynamics to develop bio-inspired vehicles based on Department of Zoology research.
USEDA doubles down on Florida’s innovation
US Economic Development Administration doubles its grant total to Florida University’s Innovation Hub.
Coursera, which enables users to take online university courses, recently raised a $49m first tranche of a $60m series C round and is setting its sights on India.
Blue Vigil drones on about funding
James Madison University spinout Blue Vigil secures $250,000 in seed round for the development of first responder aerial reconnaissance technology.
IME engineers funding for spinouts
Institution of Mechanical Engineers launches $2m fund which immediately backs spinouts.
Berkeley startup Eko secures FDA clearance for next generation stethoscope.
Catch up on all your commercialisation news with our regular roundup.
